Loomis, Sayles & Company
AGN

Loomis, Sayles & Company’s Allergan Inc AGN Stock Holding History

Loomis, Sayles & Company’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,461
Closed -$1.59M – 798
2014
Q4 		$1.59M Sell
7,461
-195,142
-96% -$38.8M ﹤0.01% 563
2014
Q3 		$36.1M Buy
202,603
+186,347
+1,146% +$30.9M 0.11% 173
2014
Q2 		$2.75M Sell
16,256
-227,281
-93% -$35.4M 0.01% 574
2014
Q1 		$30.2M Buy
243,537
+224,899
+1,207% +$27.4M 0.09% 221
2013
Q4 		$2.07M Sell
18,638
-1,850
-9% -$177K 0.01% 602
2013
Q3 		$1.85M Sell
20,488
-194,212
-90% -$17.4M 0.01% 588
2013
Q2 		$18.1K Buy
+214,700
New +$22.3M 0.06% 331

Other funds holding AGN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Loomis, Sayles & Company's AGN Position: Q1 2015 in Review

Loomis, Sayles & Company sold out of Allergan Inc (AGN) in Q1 2015, closing a stake of 7,461 shares — an estimated $1.59M sold.

Loomis, Sayles & Company first reported a position in AGN in Q2 2013 and held it in 7 quarters. The position peaked at $36.1M in Q3 2014. 5 funds tracked by Wall St. Rank hold AGN as of Q1 2015.

  • Loomis, Sayles & Company reported no remaining Allergan Inc position as of Q1 2015 after selling out during the quarter.
  • Loomis, Sayles & Company sold 7,461 Allergan Inc shares in Q1 2015, an estimated $1.59M.
  • Loomis, Sayles & Company first reported a position in Allergan Inc in Q2 2013 and held it in 7 quarters.
  • Loomis, Sayles & Company's Allergan Inc position peaked at $36.1M in Q3 2014.
  • 5 funds tracked by Wall St. Rank held Allergan Inc as of Q1 2015.

Based on Loomis, Sayles & Company's 13F filing for Q1 2015, filed 14 May 2015.